An integrated approach for prioritizing pharmaceuticals found in the environment for risk assessment, monitoring and advanced research

Chemosphere

Volumn 115, Issue 1, 2014, Pages 4-12

  Caldwell, Daniel J ^a   Mastrocco, Frank ^b   Margiotta Casaluci, Luigi ^c   Brooks, Bryan W ^d  

^a JOHNSON AND JOHNSON   (United States)

^b PFIZER INC   (United States)

^c BRUNEL UNIVERSITY   (United Kingdom)

^d BAYLOR UNIVERSITY   (United States)

Author keywords

Adverse outcome pathways; Environmental risk assessment; Intelligent testing; Pharmaceuticals in the environment; Prioritization

Indexed keywords

ENVIRONMENTAL TECHNOLOGY; HAZARDS; MAMMALS;

ACTIVE PHARMACEUTICAL INGREDIENTS; ADVANCED RESEARCHES; ADVERSE OUTCOMES; ANALYTICAL TECHNOLOGY; ENVIRONMENTAL RISK ASSESSMENT; INTELLIGENT TESTING; PRIORITIZATION; TECHNIQUES AND TOOLS;

RISK ASSESSMENT;

ACTIVE PHARMACEUTICAL INGREDIENT; CHEMICAL COMPOUND; UNCLASSIFIED DRUG; DRUG; POLLUTANT;

DATA SET; ENVIRONMENTAL ASSESSMENT; INTEGRATED APPROACH; MAMMAL; PLASMA; PRIORITIZATION; RESEARCH WORK; RISK ASSESSMENT; SURFACE WATER; TECHNOLOGICAL CHANGE;

ADVERSE OUTCOME; ARTICLE; COST EFFECTIVENESS ANALYSIS; ENVIRONMENT; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; HUMAN; NONHUMAN; POLYPHARMACOLOGY; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; TOXICITY TESTING; ADVERSE EFFECTS; ANALYSIS; ANIMAL; BIOLOGICAL MODEL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; POLLUTANT; PROCEDURES;

APIS; MAMMALIA;

ANIMALS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; POLYPHARMACOLOGY; RISK ASSESSMENT;

EID: 84921633473     PISSN: 00456535     EISSN: 18791298     Source Type: Journal    
DOI: 10.1016/j.chemosphere.2014.01.021     Document Type: Article

References (62)

1. Anderson P.D. Screening analysis of human pharmaceutical compounds in the US surface waters. Environ. Sci. Technol. 2004, 38:838-849.
2. Ankley G.T., Brooks B.W., Huggett D.B., Sumpter J.P. Repeating history: pharmaceuticals in the environment. Environ. Sci. Technol. 2007, 41:8211-8217.
3. Ankley G.T., Bennett R.S., Erickson R.J., Hoff D.J., Hornung M.W., Johnson R.D., Mount D.R., Nichols J.W., Russom C.L., Schmieder P.K., Serrano J.A., Tietge J.E., Villeneuve D.L. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 2010, 29:730-741.
4. Berninger J.P., Brooks B.W. Leveraging mammalian pharmaceutical toxicology and pharmacology data to predict chronic fish responses to pharmaceuticals. Toxicol. Lett. 2010, 193:69-78.
5. Berninger, J.P., 2011. Leveraging Available Data for Contaminants of Emerging Concern to Develop an Understanding of Environmental Hazard. Ph.D. dissertation, Baylor University, Waco, Texas.
6. Boxall A.B.A., Rudd M., Brooks B.W., Caldwell D.J., Choi K., Hickmann S., Innes E., Ostapyk K., Staveley J., Verslycke T., Ankley G.T., Beazley K., Belanger S., Berninger J.P., Carriquiriborde P., Coors A., DeLeo P., Dyer S., Ericson J., Gagne F., Giesy J.P., Gouin T., Hallstrom L., Karlsson M., Larsson D.G.J., Lazorchak J., Mastrocco F., McLaughlin A., McMaster M., Meyerhoff R., Moore R., Parrott J., Snape J., Murray-Smith R., Servos M., Sibley P.K., Straub J.O., Szabo N., Tetrault G., Topp E., Trudeau V.L., van Der Kraak G. Pharmaceuticals and personal care products in the environment: what are the big questions?. Environ. Health Perspect. 2012, 120:1221-1229.
7. Brain R.A., Ramirez A.J., Fulton B.A., Chambliss C.K., Brooks B.W. Herbicidal effects of sulfamethoxazole in Lemna gibba: using p-aminobenzoic acid as a biomarker of effect. Environ. Sci. Technol. 2008, 42:8965-8970.
8. Brausch J.M., Connors K.A., Brooks B.W., Rand G.M. Human pharmaceuticals in the aquatic environment: a critical review of recent toxicological studies and considerations for toxicity testing. Rev. Environ. Contam. Toxicol. 2012, 218:1-99.
9. Brooks B.W., Foran C.M., Richards S., Weston J.J., Turner P.K., Stanley J.K., Solomon K., Slattery M., La Point T.W. Aquatic ecotoxicology of fluoxetine. Toxicol. Lett. 2003, 142:169-183.
10. Brooks B.W., Huggett D.B., Boxall A.B.A. Pharmaceuticals and personal care products: research needs for the next decade. Environ. Toxicol. Chem. 2009, 28:2469-2472.
11. Brooks B.W., Huggett D.B., Brain R.A., Ankley G.T. Risk assessment considerations for veterinary medicines in aquatic systems. Veterinary Pharmaceuticals in the Environment 2009, 205-223. American Chemical Society, Washington DC. K. Henderson, J. Coats (Eds.).
12. Brooks B.W., Berninger J.P., Ramirez A.J., Huggett D.B. Perspectives on human pharmaceuticals in the environment. Human Pharmaceuticals in the Environment: Current and Future Perspectives, Emerging Topics in Ecotoxicology 4 2012, Springer Science+Business Media, LLC. B.W. Brooks, D.B. Huggett (Eds.).
13. Caldwell D.J., Mastrocco F., Hutchinson T.H., Länge R., Heijerick D., Janssen C., Anderson P.D., Sumpter J.P. Derivation of an aquatic predicted no-effect-concentration for the synthetic hormone, 17α-ethinyl estradiol. Environ. Sci. Technol. 2008, 42:7046-7054.
14. Christen V., Hickmann S., Rechenberg B., Fent K. Highly active human pharmaceuticals in aquatic systems: a concept for their identification based on their mode of action. Aquat. Toxicol. 2010, 96:167-181.
15. Clubbs R.L., Brooks B.W. Daphnia magna responses to a vertebrate estrogen receptor agonist and an antagonist: a multigenerational study. Ecotoxicol. Environ. Safe. 2007, 67:385-398.
16. Connors K.A., Du B., Fitzsimmons P.N., Hoffman A.D., Chambliss C.K., Nichols J.W., Brooks B.W. Comparative pharmaceutical metabolism by rainbow trout (Oncorhynchus mykiss) liver S9 fractions. Environ. Toxicol. Chem. 2013, 32:1810-1818.
17. de Voogt P., Janex-Habibi M.L., Sacher F., Puijker L., Mons M. Development of a common priority list of pharmaceuticals relevant for the water cycle. Water Sci. Technol. 2009, 59:39-46.
18. de Wolf W., Siebel-Sauer A., Lecloux A., Koch V., Holt M., Feijtel T., Comber M., Boeije G. Mode of action and aquatic exposure thresholds of no concern. Environ. Toxicol. Chem. 2005, 24:479-485.
19. Delaware River Basin Commission, 2013. Contaminants of Emerging Concern in the Tidal Delaware River, Pilot Monitoring Survey 2007-2009, Final Report July 2012 (revised 08.13).
20. Diamond J.M., Latimer H.A., Munkittrick K.R., Thornton K.W., Bartell S.M., Kidd K.A. Prioritizing contaminants of emerging concern for ecological screening assessments. Environ. Toxicol. Chem. 2011, 30:2385-2394.
21. Dong Z., Senn D.B., Moran R.E., Shine J.P. Prioritizing environmental risk of prescription pharmaceuticals. Regul. Toxicol. Pharmacol. 2013, 65:60-67.
22. Du B., Price A.E., Scott W.C., Kristofco L.A., Ramirez A.J., Chambliss C.K., Yelderman J.C., Brooks B.W. Comparison of contaminants of emerging concern removal, discharge and water quality hazards among centralized and on-site wastewater treatment systems receiving common wastewater influent. Sci. Total Environ. 2014, 466-467:976-984.
23. ECETOC, 2007. Intelligent Testing Strategies in Ecotoxicology: Mode of Action Approach for Specifically Acting Chemicals, European Centre for Ecotoxicology and Toxicology of Chemicals, Technical Report No. 102, Brussels.
24. EMA, 2006. Pre-Authorisation Evaluation of Medicines for Human Use. Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. European Medicines Agency, London, UK.
25. FDA, 1998. Guidance for Industry. Environmental Assessment of Human Drug and Biologics Applications. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Rockville, MD, USA.
26. Fent K., Weston A.A., Caminada D. Ecotoxicology of human pharmaceuticals. Aquat. Toxicol. 2006, 76:122-159.
27. Fick J., Lindberg R.H., Parkkonen J., Arvidsson B., Tysklind M., Larsson D.G.J. Therapeutic levels of levonorgestrel detected in blood plasma of fish: results from screening rainbow trout exposed to treated sewage effluents. Environ. Sci. Technol. 2010, 44:2661-2666.
28. Gunnarsson L., Jauhiainen A., Kristiansson E., Nerman O., Larsson D.G.J. Evolutionary conservation of human drug targets in organisms used for environmental risk assessments. Environ. Sci. Technol. 2008, 42:5807-5814.
29. Harris C.A., Patrick B., Hamilton P.B., Runnalls T.J., Vinciotti V., Henshaw A., Hodgson D., Coe T.S., Jobling S., Tyler C.R., Sumpter J.P. The consequences of feminization in breeding groups of wild fish. Environ. Health Perspect. 2011, 119:306-311.
30. Heberer T. Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicol. Lett. 2002, 131:5-17.
31. Huggett D.B., Cook J.C., Ericson J.E., Williams R.T. A theoretical model for utilizing mammalian pharmacology and safety data to prioritise potential impacts of human pharmaceuticals to fish. J. Human Ecol. Risk Assess. 2003, 9:1789-1799.
32. Johnson, A.C., Dumont, E., Williams, R.J., Oldenkamp, R., Cisowska, I., Sumpter, J.P., in press. Do concentrations of ethinylestradiol, estradiol, and diclofenac in European rivers exceed proposed EU Environmental Quality Standards? Environ. Sci. Technol. doi: 10.1021/es4030035.
33. KNAPPE, 2008. Knowledge and need assessment of pharmaceutical products in environmental waters, Final Report, European Commission FP6 project 036864, http://environmentalhealthcollaborative.org/images/KNAPPE_REPORT_FINAL.pdf.
34. Kostich M.S., Lazorchak J.M. Risks to aquatic organisms posed by human pharmaceutical use. Sci. Total Environ. 2008, 389:329-339.
35. Kugathas S., Runnalls T.J., Sumpter J.P. Metabolic and reproductive effects of relatively low concentrations of beclomethasone dipropionate, a synthetic glucocorticoid, on fathead minnows. Environ. Sci. Technol. 2013, 47(16):9487-9495.
36. Larsson D.G.J., de Pedro C., Paxeus N. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J. Hazard. Mater. 2007, 148:751-755.
37. Li D., Yang M., Hu J., Ren L., Zhang Y., Li K. Determination and fate of oxytetracycline and related compounds in oxytetracycline production wastewater and the receiving river. Environ. Toxicol. Chem. 2008, 27:80-86.
38. Lounkine E., Keiser M.J., Whitebread S., Mikhailov D., Hamon J., Jenkins J.L., Lavan P., Weber E., Doak A.K., Cote S., Shoichet B.K., Urban L. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012, 486:361-367.
39. Margiotta-Casaluci L., Hannah R.E., Sumpter J.P. Mode of action of human pharmaceuticals in fish: the effects of the 5-alpha-reductase inhibitor, dutasteride, on reproduction as a case study. Aquat. Toxicol. 2013, 128-129:113-123.
40. Moen, M.A., Owen, S.F., Hutchinson, T.H., Hetheridge, M.J., Constantine, L.A., Sumpter, J.P., Huggett, D.B., 2007. Pharmaceutical plasma concentrations in fish as a prediction tool for toxicity: case studies with 17α-ethinyl estradiol and propranolol. SETAC North America, 29th Annual Meeting.
41. O.J., 2013. (L 226) 1. Directive of the European Parliament and of the Council of 12 August 2013 amending Directives 2000/60/EC and 2008/105/EC as regards priority substances in the field of water policy - 17 April 2013.
42. OECD, 2011a. (Draft) The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins.
43. OECD, 2011b. Report of the Workshop on Using Mechanistic Information in Forming Chemical Categories. OECD Environment, Health and Safety Publications Series on Testing and Assessment No. 138. ENV/JM/MONO(2011) 8.
44. OECD, 2012. Proposal for a template, and guidance on developing and assessing the completeness of adverse outcome pathways.
45. Oldenkamp R., Huijbregts M.A.J., Hollander A., Versporten A., Goossens H., Ragas A.M.J. Spatially explicit prioritization ofhuman antibiotics and antineoplastics in Europe. Environ. Int. 2013, 51:13-26.
46. Owen S.F., Huggett D.B., Hutchinson T.H., Hetheridge M.J., Kinter L.B., Ericson J.F., Sumpter J.P. Uptake of propranolol, a cardiovascular pharmaceutical, from water into fish plasma and its effects on growth and organ biometry. Aquat. Toxicol. 2009, 93:217-224.
47. Phillips P.J., Smith S.G., Kolpin D.W., Zaugg S.D., Buxton H.T., Furlong E.T., Esposito K., Stinson B. Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents. Environ. Sci. Technol. 2010, 44:4910-4916.
48. Raimondo S., Hemmer B.L., Goodman L.R., et al. Multigenerational exposure of the estuarine sheepshead minnow (cyprinodon variegatus) to 17b-Estradiol. II. Population-Level Effects through two life cycles. Environ. Toxicol. Chemistry 2009, 28(11):2409-2415.
49. Rand-Weaver M., Margiotta-Casaluci L., Patel A., Panter G.H., Owen S.F., Sumpter J.P. The read-across hypothesis and environmental risk assessment of pharmaceuticals. Environ. Sci. Technol. 2013, 47(20):11384-11395.
50. Rang H.P., Dale M.M., Ritter J.M., Moore P.K. Pharmacology 2003, Churchill-Livingstone, Edinburgh, p. 797. fifth ed.
51. Roos V., Gunnarsson L., Fick J., Larsson D.G.J., Ruden C. Priortising pharmaceuticals for environmental risk assessment: towards adequate and feasible first-tier selection. Sci. Total Environ. 2012, 421-422:102-110.
52. Runnalls T.J., Beresford N., Losty E., Scott A.P., Sumpter J.P. Several synthetic progestins with different potencies adversely affect reproduction in fish. Environ. Sci. Technol. 2013, 47:2077-2084.
53. Seiler J.P. Pharmacodynamic activity of drugs and ecotoxicology - can the two be connected?. Toxicol. Lett. 2002, 131:105-115.
54. Small, J., Caldwell, D.J., Constantine, L. et al. submitted for publication. Use of Acute and Chronic Ecotoxicity Data in Environmental Risk Assessment of Pharmaceuticals, Environ. Toxicol. Chemistry.
55. Sumpter J.P., Jobling S. The occurrence, cause and consequences of estrogens in the aquatic environment. Environ. Toxicol. Chem. 2013, 32:249-251.
56. Valenti T.W., Taylor J.T., Back J.A., King R.S., Brooks B.W. Influence of drought and total phosphorus on diel pH in wadeable streams: Implications for ecological risk assessment of ionizable contaminants. Integr. Environ. Assess. Manage. 2011, 7:636-647.
57. Valenti T.W., Gould G.G., Berninger J.P., Connors K.A., Keele N.B., Prosser K.N., Brooks B.W. Human therapeutic plasma levels of the selective serotonin reuptake inhibitor (SSRI) sertraline decrease serotonin reuptake transporter binding and shelter seeking behaviour in adult male fathead minnows. Environ. Sci. Technol. 2012, 46:2427-2435.
58. Verhaar H.J.M., van Leeuwen C.J., Hermens J.L.M. Classifying environmental pollutants. 1: structure-activity relationships for prediction of aquatic toxicity. Chemosphere 1992, 25:471-491.
59. Volz D.C., Belanger S., Embry M., Padilla S., Sanderson H., Schirmer K., Scholz S., Villeneuve D. Adverse outcome pathways during early fish development: a conceptual framework for identification of chemical screening and prioritization strategies. Toxicol. Sci. 2011, 123:349-358.
60. Walker F.R. A review of the mechanism of action for selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and is this relevant in the treatment of depression?. Neuropharmacology 2013, 67C:304-317.
61. Winter M.J., Owen S.F., Murray-Smith R., Panter G.H., Hetheridge M.J., Kinter L.B. Using data from drug discovery and development to aid the aquatic environmental risk assessment of human pharmaceuticals: concepts, considerations, and challenges. Integr. Environ. Assess. Manage. 2010, 6:38-51.
62. Zeilinger J., Steger-Hartmann T., Maser E., Goller S., Vonk R., Länge R. Effects of synthetic gestagens on fish reproduction. Environ. Toxicol. Chem. 2009, 28(12):2663-2670.